DOCSLIB.ORG

Front Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Front Matter (PDF) Not al drgfr the treatmnentofAH are iaentical- infrmnulation, clinicalactity1 or dosingfeqency te onl protduct tat contains both dextro ()and levo aI)apetamnine Usae dtaaorADRl indiae tat nmostpatients can be mnaintained on a once- or twice-diladIosing re( i?en n=611 children aged 3 to 12 who had at least three office visits during the 1-year, ADDERALL usage period (March 1995 to February 1996)- 34 patients receiving greater than 40 mg per day were excluded from this analysis.' Clinical actvyVI * ADDERALL has a product half-life of 8 to 12 hours',' * The safety profile of amphetamine products like ADDERALL has been confirmed over years of clinical use * ADDERALL is generally well tolerated- adverse reactions have seldom been reported (most frequently reported adverse reactions include anorexia, insomnia, stomach pain, headache, irritability, and weight loss)' * As with most psychostimulants indicated for ADHD, the possibility of growth suppressil'on and the potential for precipitating motor tics and Tourette's syndrome exists wvith ADDERALL treatment, and, in rare cases, exacerbations of psychosis have been reported' . Since amphetamnines have a hig potential for abuse, ADDERALL should only be prescribed as part of an overall multimodal treatment program,for ADHD wvith -dose physilciaii supervision * ADDERALL is safe and effective in younger children~ indicated for use in children 3 years of age anld older' . The starting dose ofADDERALL: 3 to 5 years: 2.5 mg daily; 6 years of age and older: 5 mg once or twvice daily . ADDERALL is available in 10 mg and 20 mg double-scored tablets for optimal dosing flexibility ~~Offers precise dosage coffelation with individual therapeutic needs T4itrate to optimal dose with a singl prescription 10 mgblue double-scored tablet 20 mgorange double-scored tablet -1 O nag &k 20 nag YABL-EYS (Mixed Salts of a Single-Entity Amphetamine Product) Dextroamphetamine Sulfate Amphetamine Sulfate Pleaseseereferencesand briefsummary Dextroamphetamine Saccharate Amphetamine Aspartate ofprescribing information on adjacentpage. J&Ow ce g ...working to becomeyourADIID support company 11 w hom, -~e j {~atastth ereare athree tievv acellular vaccines clairming , ~~ r4 an W to be evateet a T Infanrixll: The only U.S.olicensed acellular DTP vaccine proven more efecive than whole-cell DTP Acellular DTP vaccines cause fewer local and systemic side effects than whole-cell vaccines.'-4But only one, Infanrix, has been proven more effective against pertussis than a U.S.-licensed whole-cell DTP vaccine, manufactured by Connaught Laboratories, in an NIH-sponsored study recently published in The New England Journal of Medicine.' InfanrixT: Why 3 components? The results of two NIH-sponsored clinical trials reported in The New England Joumal of Medicine supported the efficacy of three-pertussis-antigen Intanfix.1 4,5 Infanrixll: Because children deserve all the proection they can get. Local adverse events may occur at the site of injection and include erythema, swelling and tenderness. Systemic adverse events may include fever, irritability and drowsiness. Hypersensitivity to any component of Infannix is a contraindication. As with any vaccine, vaccination with Infantix may not protect 1 00°h of susceptible individuals. Rene: 1. Greco D, Salmaso S, Mastrantonio P, et a]. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341 -348. 2. Decker MD, Edwards KM, Steinhoff MC, et a]. Compa~rison of 13 acellular pertussis vaccines: adverse reactions. Pediatnics 1995;96(suppl):557-566. 3. Infanrnx Prescribing Information, SmithKline Beecham Pharrna- ceuticals. 4. Gustafsson L, Hallander HO, Olin P, et a]. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-355. 5. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996;334:391 -392. Editorial. Please see brief summary of prescribing information on adjacent page. Inroducing r------------------------------------------------~---------------- P A T I E N 11r xI NXT r'10 1%J 1DMfnIL 5 AA 9r1 1lT J PREVERT1XkT ------------------------------------------------------------------IPOISO0l0G~~~~~~~~~~~~~~~~~I Lock up medicines S f g;0f Keep up with the times Keep all medicines and potentially Discard substances used for old- Idangerous household substances fashioned treatments, such as: oil of out of reach of children, in cabinets with wintergreen, boric acid, ammoniated child-protection safety latches. Store mercury, oil of turpentine and camphor- medicines away from household prod- ated oil. ucts. Keep household products away from food. Do not be distracted 7If the phone or doorbell rings while Use original Iyou are administering medicine containers or using a potentially poisonous product, secure the product you are using: Keep medicines or household prod- Replace its cap, put it back in the Cucts in their properly labeled original cupboard, or take it or the child with containers. Original packaging is usually you while dealing with the distraction. required to contain child safety pre- cautions. Labels include information Plan ahead for control centers in case of poison QEducate your children. Post the poi- an Never emergency. put dangerous son control center phone number products in containers from which with other emergency numbers by every people eat or drink. phone. Keep ipecac syrup on hand so that if the poison control center advises Use child-resistant you to administer it, you are prepared. packaging Support poison control centers. (2Credited with saving at least 700 zJchildren's lives since its introduction Set a good example in 1970, child-resistant packaging Do not take medicines in front of is still often used improperly, according ;7children. Do not drink from contain- to the U.S. Consumer Product Safety ers, such as cough syrup bottles. Never Commission (CPSC). Be sure to replace refer to medicine as "candy." Children caps securely. Adult-friendly packaging are likely to imitate and could adopt now makes it easier for arthritic these behaviors. hands or frustrated adults to protect chil- dren without inconvenienced from home being The of are - Away themselves. signs potential poisoning frightening vomiting, appearing sluggish or drowsy, substance or burns around the mouth or a smell on the child's breath. dnSome 23 percent of poisonings But clear and deliberate actions will ensure the most efficient care for |Jinvolve prescription drugs belong- Read the label thinking ing to someone the child does not live the child. A plan of attack will help in such an emergency. ADo not administer medicine in the with, most often grandparents, according dark. Do not trust your memory for 1. Remain calm. to an American Association of Poison dosage instructions. Use your eyeglass- Control Centers study. Thirteen percent of es or contacts to read the fine print. 2. Call the poison control center prepared to give: all child poisonings occur in homes other LJvictim's age than the child's, according to the CPSC. Dispose of outdated Li victim's weight - Rebecca Palmer medicines Li any pre-existing health conditions or problems ,When you regularly clean out your LI substance involved vJmedicine cabinets, flush medicine FiVQ plants most (ommonM4 down the drain or toilet, and then rinse LI quantity of substance associated with poisoning~s the bottles before throwing them in Li time of exposure the trash. OJ whether substance was swallowed, inhaled, absorbed C) Pepper (the spice) through skin, splashed into eyes C) Philodendron (Philoclendron scandens or P. selloum) Li progression of symptoms Most Dangerous Medidffls Dieffenbtachia _ LI your location a'nd how long it takes to reach a hospital O) Ironsupplements (Dieffenbachia 3. Follow the specific instructions of the poison control center. maculata or CO Cardiovasculardrugs 4. Continue poison prevention. D. sequinwe)_ Anti-depressants pi II Be prepared for a poisoning emergency: Post the poison control center phone number by every phone. TO LOCATE THE NEAREST POISON CONTROL CENTER, call (202) 362-7217, or write to the American Association of Poison Control Centers, 3201 New Mexico Avenue, NW, Suite 310, Washington, DC 20016. ma[Ch 16-22 ~~~~~1 March 1997AAPNews IS ,g. x,j1 7# -' 1-1. :,.?A ,'O,*Z. ov ..i I t"'. t, *N. I" #t^. , ,*,., , PI:40 7'* ;-'_ fs 07.j A.l 1 - IL "I 5 m I I X_ C v _ G~~A No,o E HE w ^ .... ;. .~~I _ t:ff:ft:040 00 00_:= S *se ._r~~~ a a0 07fi000 IPCDlease see briefsummary for ZYRTEC tablets and syrup on the following page. Based on a comparison of the list price to wholesalers (wholesale acquisidon cost) of ZYKTEC tablets, Claridn, Seldane, Hismanal, Clarittin-D, Seldane-D, and Allegra on a cost/day basis; Actual cost to patients may vary. Medispon, December, 1996. Due caution should be exemised when driving a car or opemting potentially dangerous machinery. BRIEF SUMMARY ZYRTEV (CETIRIZINE HYDROCHLORIDE) TABLETS MD SYRUP FOR ORAL USE FOR FULL PRESCRIBING INFORMATION, CONSULT PACKAGE INSERT) INDICATIONS AND USAGE Seasonal Allergic Rhinitis: ZYRTEC is indicated for the relief of symptoms associated with seasonal allergic rhinitis due to allergens such as ragweed, grass and tree pollens in adufts and children 6 yearsof age Md older. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing and redness of the eyes. Perennial Allergic Rhinitis: ZYRTEC is indicated for the relief of sym toms associated with perennial allergic rhinitis due to aller ens such as dust mites, animal dan- der and molds in adults and children T years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal ruritus, ocular pruritus and tearing. Chmnit UrOcaria: ZYRTEC is indicated for the treatrnent ot the uncomplicated skin manifestations ofchronic idiopathic udicaria in adufts and children 6 years of age and older. It significantly reduces the occurrence, sever- ity and duration of hives and si nificantly reduces pruritus. CONTRAINDICATIONS ZYR?EC is contraindicated in those patientswith a known hypersensitivityto it or any of its ingredients or hydrox- yzine.
Load more

Recommended publications
  • Parosmia Due to COVID-19 Disease: a 268 Case Series
    Parosmia due to COVID-19 Disease: A 268 Case Series Rasheed Ali Rashid Tikrit University, College of Medicine, Department of Surgery/ Otolaryngology Ameer A. Alaqeedy University Of Anbar, College of Medicine, Department of Surgery/ Otolaryngology Raid M. Al-Ani ( [email protected] ) University Of Anbar, College of Medicine, Department of Surgery/Otolaryngology https://orcid.org/0000-0003-4263-9630 Research Article Keywords: Parosmia, COVID-19, Quality of life, Olfactory dysfunction, Case series Posted Date: May 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-506359/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Although parosmia is a common problem in the era of the COVID-19 pandemic, few studies assessed the demographic and clinical aspects of this debilitating symptom. We aimed to evaluate the socio-clinical characteristics and outcome of various options of treatment of individuals with parosmia due to COVID- 19 infection. The study was conducted at two main Hospitals in the Ramadi and Tikrit cities, Iraq, on patients with a chief complaint of parosmia due to COVID-19 disease. The study involved 7 months (August 2020-February 2021). Detailed demographic and clinical characteristics and treatment options with their outcome were recorded and analyzed. Out of 268 patients with parosmia, there were 197 (73.5%) females. The majority were from age group ≤ 30 years (n = 188, 70.1%), housewives (n = 150, 56%), non-smokers (n = 222, 82.8%), and associated with dysgeusia (n = 207, 77.2%) but not associated with nasal symptoms (n = 266, 99.3%).
    [Show full text]
  • Taste and Smell Disorders in Clinical Neurology
    TASTE AND SMELL DISORDERS IN CLINICAL NEUROLOGY OUTLINE A. Anatomy and Physiology of the Taste and Smell System B. Quantifying Chemosensory Disturbances C. Common Neurological and Medical Disorders causing Primary Smell Impairment with Secondary Loss of Food Flavors a. Post Traumatic Anosmia b. Medications (prescribed & over the counter) c. Alcohol Abuse d. Neurodegenerative Disorders e. Multiple Sclerosis f. Migraine g. Chronic Medical Disorders (liver and kidney disease, thyroid deficiency, Diabetes). D. Common Neurological and Medical Disorders Causing a Primary Taste disorder with usually Normal Olfactory Function. a. Medications (prescribed and over the counter), b. Toxins (smoking and Radiation Treatments) c. Chronic medical Disorders ( Liver and Kidney Disease, Hypothyroidism, GERD, Diabetes,) d. Neurological Disorders( Bell’s Palsy, Stroke, MS,) e. Intubation during an emergency or for general anesthesia. E. Abnormal Smells and Tastes (Dysosmia and Dysgeusia): Diagnosis and Treatment F. Morbidity of Smell and Taste Impairment. G. Treatment of Smell and Taste Impairment (Education, Counseling ,Changes in Food Preparation) H. Role of Smell Testing in the Diagnosis of Neurodegenerative Disorders 1 BACKGROUND Disorders of taste and smell play a very important role in many neurological conditions such as; head trauma, facial and trigeminal nerve impairment, and many neurodegenerative disorders such as Alzheimer’s, Parkinson Disorders, Lewy Body Disease and Frontal Temporal Dementia. Impaired smell and taste impairs quality of life such as loss of food enjoyment, weight loss or weight gain, decreased appetite and safety concerns such as inability to smell smoke, gas, spoiled food and one’s body odor. Dysosmia and Dysgeusia are very unpleasant disorders that often accompany smell and taste impairments.
    [Show full text]
  • Smell Distortions: Prevalence, Longevity and Impact of Parosmia in a Population-Based, Longitudinal Study Spanning 10 Years
    Smell distortions: Prevalence, longevity and impact of parosmia in a population-based, longitudinal study spanning 10 years Jonas K. Olofsson*1, Fredrik Ekesten1, & Steven Nordin2 1Department of Psychology, Stockholm University, Stockholm, Sweden 2Department of Psychology, Umeå University, Umeå, Sweden *Corresponding author: [email protected] Abstract. Parosmia, experiences of distorted smell sensations, is a common consequence of covid-19. The phenomenon is not well understood in terms of its impact and long-term outcomes. We examined parosmia in a population-based sample from the Betula study that was conducted in Umeå in northern Sweden (baseline data collected in 1998-2000). We used a baseline sample of 2168 individuals aged 35-90 years and with no cognitive impairment at baseline. We investigated the prevalence of parosmia and, using regression analyses, its relationship to other olfactory and cognitive variables and quality of life. Benefitting from the longitudinal study design, we also assessed the persistence of parosmia over 5 and 10 years prospectively. Parosmia was prevalent in 5% of the population (n=104) and was often co- occurring with phantosmia (“olfactory hallucinations”), but was not associated with lower self-rated overall quality of life or poor performance on olfactory or cognitive tests. For some individuals, parosmia was retained 5 years (17%) or even 10 years later (10%). Thus, parosmia is relative common in the population, and can be persistent for some individuals. This work provides rare insights into the expected impact of, and recovery from parosmia, with implications for those suffering from qualitative olfactory dysfunction following covid-19. 2 Introduction Parosmia is an olfactory disorder (OD) where odor perception is distorted and different stimuli trigger unpleasant odor sensations previously not associated with the stimuli (i.e.
    [Show full text]
  • Sixty Seconds on . . . Parosmia
    NEWS The BMJ BMJ: first published as 10.1136/bmj.m4332 on 9 November 2020. Downloaded from Cite this as: BMJ 2020;371:m4332 Sixty seconds on . parosmia http://dx.doi.org/10.1136/bmj.m4332 Abi Rimmer Published: 09 November 2020 I’ve heard of anosmia but what's this? The charity Fifth Sense explains that parosmia is the medical term for distortions of the sense of smell. Someone with parosmia may be able to detect odours, but the smell of certain things—or sometimes everything—is different, and often unpleasant.1 Such as? Jennifer Spicer, a US based infectious diseases doctor, said that following her recovery from covid-19, coffee, wine, and other foods tasted like gasoline.2 Nicola Watt, who also recovered from the virus, described similar symptoms to the Times.3 “Quite suddenly everything smelt and tasted like a horrid rubbish bin,” Watt said. Sounds awful. Is this from covid-19? Not specifically. Parosmia is common with all types of post-viral smell loss, and over half of people who have lost their sense of smell because of a virus will go on to experience it.4 Fragrance writer Louise Woollam, for example, suffered from parosmia after a cold and found that most foods tasted of sewage or mud and most things smelt disgusting.5 How awful! Yes, and what’s worse Woollam, like many other people, experienced phantosmia as well when “phantom” smells appear in the absence of any odour. These can manifest as “normal” smells – for example, being able to smell garlic when there is no garlic present – but they can also be unpleasant.1 Is there a cure? Unfortunately not.
    [Show full text]
  • Clinical Diagnosis and Treatment of Olfactory Dysfunction
    Clinical Diagnosis and Treatment of Olfactory Dysfunction Seok Hyun Cho Hanyang Med Rev 2014;34:107-115 http://dx.doi.org/10.7599/hmr.2014.34.3.107 Department of Otorhinolaryngology-Head and Neck Surgery, Hanyang University College of Medicine, Seoul, Korea pISSN 1738-429X eISSN 2234-4446 Olfactory dysfunction is a relatively common disorder that is often under-recognized by Correspondence to: Seok Hyun Cho Department of Otorhinolaryngology-Head both patients and clinicians. It occurs more frequently in older ages and men, and decreases and Neck Surgery, Hanyang University patients’ quality of life, as olfactory dysfunction may affect the emotion and memory func- Hospital, 222 Wangsimni-ro, Seongdong-gu, tions. Three main causes of olfactory dysfunction are sinonasal diseases, upper respiratory Seoul 133-792, Korea Tel: +82-2-2290-8583 viral infection, and head trauma. Olfactory dysfunction is classified quantitatively (hypos- Fax: +82-2-2293-3335 mia and anosmia) and qualitatively (parosmia and phantosmia). From a pathophysiologi- E-mail: [email protected] cal perspective, olfactory dysfunction is also classified by conductive or sensorineural types. All patients with olfactory dysfunction will need a complete history and physical examina- Received 17 April 2014 Revised 23 June 2014 tion to identify any possible or underlying causes and psychophysical olfactory tests are Accepted 3 July 2014 essential to estimate the residual olfactory function, which is the most important prognos- This is an Open Access article distributed under tic factor. CT or MRI may be adjunctively used in some indicated cases such as head trauma the terms of the Creative Commons Attribution and neurodegenerative disorders.
    [Show full text]
  • Will My Patient Attempt Suicide Again?
    Will my patient attempt suicide again? Risk factors help you identify patients who need immediate hospitalization for safety ® Dowden Health Media s. J, age 32, comes to our mental health clinic seeking treatment for depression and anxi- Mety. She reportsCopyright she has attemptedFor personal suicide use only 3 times. Ms. J describes the first 2 attempts—both of which occurred when she was in her 20s after the end of a relationship—as “cries for attention” that were rela- tively innocuous. Her third suicide attempt, however, was an acetaminophen overdose approximately 1 year ago that resulted in hospitalization and irreversible liver damage. VEER Ms. J acknowledges that over the last several weeks / she has been thinking about suicide almost constantly, HAMELS especially as the anniversary of her fiancé’s death ap- proaches. She says she has a nearly full bottle of zolpi- LAURENT © dem in her medicine cabinet and fantasizes about taking all of them and just “going to sleep.” Elizabeth L. Jeglic, PhD Associate professor Department of psychology Many patients—especially those with depression—ex- John Jay College of Criminal Justice perience recurrent thoughts of death or a wish to die, New York, NY but only about 10% attempt suicide.1 To identify those who are at highest risk and warrant hospitalization, it is vital to assess how a history of suicidal behavior and other factors impact the risk for future suicide at- tempts. This article: • examines research on patients who have attempted suicide and risk factors for repeat suicide attempts • describes characteristics of patients with multiple attempts • explores the link between a history of self-injurious Current Psychiatry behavior and suicide attempts.
    [Show full text]
  • Can Clinical Staging of Primary Amoebic Meningoencephalitis Be of Any Therapeutic Benefit Abdul Mannan Baig Dr
    eCommons@AKU Department of Biological & Biomedical Sciences Medical College, Pakistan January 2017 Can clinical staging of primary amoebic meningoencephalitis be of any therapeutic benefit Abdul Mannan Baig Dr. Aga Khan University, [email protected] Armaghan-e-Rehman Mansoor [email protected] Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs Recommended Citation Baig, A. M., Mansoor, A. (2017). Can clinical staging of primary amoebic meningoencephalitis be of any therapeutic benefit. EC MICROBIOLOGY, 5(3), 101-108. Available at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs/300 Cronicon OPEN ACCESS EC MICROBIOLOGY Review Article Can Clinical Staging of Primary Amoebic Meningoencephalitis be of any Therapeutic Benefit? Abdul Mannan Baig* and Armaghan-e-Rehman Mansoor The Aga Khan University, Karachi, Pakistan *Corresponding Author: The Department of BBS, Aga Khan University, Medical College, Karachi, Pakistan. Received: December 15, 2016; Published: January 19, 2017 Summary Naegleria fowleri, is a free-living amoeba (FLA) known to infect humans and cause a fatal disease called primary amoebic menin- goencephalitis (PAM). All of the patients are commonly admitted to the emergency room (ER). Often, treatment in the ER is delayed due to the rarity of disease leading to a delay in the diagnosis and late arrival of patients to the ER. The attempts to reduce raised intracranial pressure and subsequent herniation of the brain stem are challenging and become the cause of death in the affected patients during their stay in ER. Use of drugs like mannitol to reduce raised intra-cerebral pressure (ICP) could prove dangerous in the presence of cerebral haemorrhage and this fact could be overlooked during the management of patients with PAM.
    [Show full text]
  • PAROXETINE TABLETS, USP 10 Mg, 20 Mg, 30 Mg and 40 Mg Rx Only
    PAROXETINE- paroxetine hydrochloride tablet, film coated REMEDYREPACK INC. ---------- PAROXETINE TABLETS, USP 10 mg, 20 mg, 30 mg and 40 mg Rx only Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of paroxetine tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Paroxetine tablets are not approved for use in pediatric patients (see WARNINGS, Clinical Worsening and Suicide Risk, PRECAUTIONS, Information for Patients, and PRECAUTIONS, Pediatric Use). DESCRIPTION Paroxetine hydrochloride is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans-4 R-(4'-fluorophenyl)-3 S-[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride anhydrous and has the empirical formula of C 19H 20FNO 3•HCl . The molecular weight is 365.8 (anhydrous) (329.4 as free base).
    [Show full text]
  • Topamax® Tablets and Sprinkle Capsules Topiramate New Zealand Data Sheet
    TOPAMAX® TABLETS AND SPRINKLE CAPSULES TOPIRAMATE NEW ZEALAND DATA SHEET 1. PRODUCT NAME TOPAMAX® 25 mg, 50 mg, 100 mg & 200 mg film-coated tablets TOPAMAX® Sprinkle 15 mg, 25 mg & 50 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION TABLETS Each tablet contains 25 mg, 50 mg, 100 mg or 200 mg of topiramate. Excipient(s) with known effect: Lactose monohydrate For a full list of excipients, see section 6.1. SPRINKLE CAPSULES Each capsule contains 15 mg, 25 mg or 50 mg of topiramate. Excipients with known effect: Sugar For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM TABLETS 25 mg: Round, white, film-coated tablets, marked “TOP” on one side and “25” on the other. 50 mg: Round, light-yellow, film-coated tablets, marked “TOP” on one side and “50” on the other 100 mg: Round, yellow, film-coated tablets, marked “TOP” on one side and “100” on the other 200 mg: Round, salmon, film-coated tablets, marked “TOP” on one side and “200” on the other. SPRINKLE CAPSULES Hard capsules enclosing small, white to off-white spheres. Each gelatin capsule consists of a clear (natural) capsule cap and a white capsule body. 15 mg: imprinted with “TOP” on cap and “15 mg” on body 25 mg: imprinted with “TOP” on cap and “25 mg” on body 50mg: imprinted with “TOP” on cap and “50mg” on body (not marketed). CCDS201005v23 1 TOPAMAX(201215)ADS 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS EPILEPSY TOPAMAX is indicated in adults and children, 2 years and over: • as monotherapy in patients with newly diagnosed epilepsy • for conversion to monotherapy in patients with epilepsy • as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.
    [Show full text]
  • REMERON/Remeronsoltab with Caution These Highlights Do Not Include All the Information Needed to Use in Patients with Risk Factors for QT Prolongation
    HIGHLIGHTS OF PRESCRIBING INFORMATION QT Prolongation: Use REMERON/REMERONSolTab with caution These highlights do not include all the information needed to use in patients with risk factors for QT prolongation. (5.5, 7) REMERON/REMERONSolTab safely and effectively. See full Increased Appetite/Weight Gain: REMERON/REMERONSolTab prescribing information for REMERON/REMERONSolTab. has been associated with increased appetite and weight gain. (5.6) ® REMERON (mirtazapine) tablets, for oral use Somnolence: May impair judgment, thinking and/or motor skills. ® REMERONSolTab (mirtazapine) orally disintegrating tablets Use with caution when engaging in activities requiring alertness, Initial U.S. Approval: 1996 such as driving or operating machinery. (5.7, 7) Activation of Mania/Hypomania: Screen patients for bipolar WARNING: SUICIDAL THOUGHTS AND BEHAVIORS disorder prior to initiating treatment. (2.3, 5.8) See full prescribing information for complete boxed warning. Seizures: Use with caution in patients with a seizure disorder. (5.9) Increased risk of suicidal thoughts and behavior in pediatric and Elevated Cholesterol/Triglycerides: Has been reported with young adult patients taking antidepressants. Closely monitor all REMERON use. (5.10) antidepressant-treated patients for clinical worsening and Hyponatremia: May occur as a result of treatment with emergence of suicidal thoughts and behaviors. serotonergic antidepressants, including REMERON/REMERONSolTab is not approved for use in pediatric REMERON/REMERONSolTab. (5.11) patients. (5.1,
    [Show full text]
  • Anosmia, Parosmia and the Impact of Long Covid-19
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.26.20239152; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Altered Smell and Taste: anosmia, parosmia and the impact of long Covid-19 Dr Duika L Burges Watson (Altered Eating Research Network, Faculty of Medical Sciences, Newcastle University, UK) Dr Miglena Campbell (Altered Eating Research Network, Centre for Applied Psychological Science, Teesside University, UK) Professor Claire Hopkins (Professor of Rhinology, King’s College, London, UK) Professor Barry Smith (Director of the Institute of Philosophy, University of London, UK) Chris Kelly (AbScent, UK) Professor Vincent Deary (Altered Eating Research Network, Psychology, Northumbria University, UK) Abstract Background: Qualitative olfactory (smell) dysfunctions are a common side effect of post- viral illness and known to impact on quality of life and health status. Evidence is emerging that taste and smell loss are common symptoms of Covid-19 that may emerge and persist long after initial infection. The aim of the present study was to document the impact of post Covid-19 alterations to taste and smell. Methods: We conducted passive and active thematic analysis of user-generated text from 9000 users of the AbScent Covid-19 Smell and Taste Loss moderated Facebook support group from March 24 to 30th September 2020. Results: Participants reported difficulty understanding, explaining and managing altered taste and smell; a lack of interpersonal and professional explanation or support; altered eating; appetite loss, weight change; loss of pleasure in food, eating and social engagement; altered intimacy and an altered relationship to self and others.
    [Show full text]
  • Self-Reported Olfactory and Gustatory Dysfunction in Patients with COVID-19 Infection*
    ORIGINAL CONTRIBUTION Self-reported olfactory and gustatory dysfunction in patients with COVID-19 infection* 1 1 2 D. Kooper , H.Coerts , H. Mkadmi Rhinology Online, Vol 4: 140 - 146, 2021 http://doi.org/10.4193/RHINOL/20.088 1 Department of Otorhinolaryngology, Reinier de Graaf Gasthuis, Delft, The Netherlands 2 Department of Medical Research, Reinier de Graaf Gasthuis, Delft, The Netherlands *Received for publication: December 4, 2020 Accepted: August 11, 2021 Published: August 17, 2021 Abstract Objective: To investigate the incidence, comorbidity and recovery period of smell and taste loss in patients with COVID-19 infec- tion, who were treated as outpatient or admitted to the hospital. Methods: 103 patients with COVID-19 infection were recruited from a COVID-19 Test Centre (CTC) and hospital wards. Subjects fil- led in an online self-report survey retrospectively at least six months after recruitment. The following epidemiological and clinical outcomes have been studied: age, gender, comorbidities, general and otolaryngological symptoms and recovery of the olfactory or gustatory loss. Results: All patients suffered from mild to severe respiratory disease. A high frequency of smell and taste dysfunctions was reported (71.2% and 78.9% respectively). 33% of the patients reported anosmia and 33% reported ageusia. The most frequent symptoms were fever, loss of smell and taste, dyspnoea and headache. The most common comorbidities were hypertension, obesity and diabetes. Males suffered 2.6 times more often from olfactory dysfunction than females. No statistical difference with regard to recovery time were found between man and women. There was a significant difference in the sense of taste scores before COVID-19 infection and during COVID-19 infection.
    [Show full text]